Recognition and Phagocytosis of Candida Albicans by the innate immune system
先天免疫系统对白色念珠菌的识别和吞噬作用
基本信息
- 批准号:7408805
- 负责人:
- 金额:$ 5.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-12-01 至 2010-11-30
- 项目状态:已结题
- 来源:
- 关键词:AntibodiesAntigensBindingBiological MarkersCandidaCandida albicansCell WallCell surfaceCellsChitinClassificationComplementConditionDetectionDevelopmentDissectionDisseminated candidiasisEnvironmentEpitopesFilamentFungal ComponentsGene DeletionGenesGenomeGlucansGoalsHumanImmuneImmune responseImmune systemInflammatory ResponseLibrariesLifeMammalian CellMannansMasksMedicalMethodsMorphogenesisMutationNumbersPathogen detectionPathogenesisPathway interactionsPhagocytosisPhagocytosis InductionPhagosomesPharmacologic SubstanceProcessProteinsPublic HealthRNA InterferenceRateRegulatory PathwayRoleSiteStarfishSubfamily lentivirinaeSurfaceSystemTimeTissuesYeastsbasecytokinedectin 1deletion librarydrug developmentfungusimmune functionimmunogenickillingsmacrophagemannoproteinsmortalitymutantnew technologypathogenprogramsreceptorresponsesuccesstool
项目摘要
DESCRIPTION (provided by applicant): Candida albicans, the most frequently isolated human fungal pathogen, has developed several mechanisms to evade immune detection and killing. First, Candida is able to mask immunogens in its cell wall. Second, upon phagocytosis by macrophages, Candida is able to undergo hyphal morphogenesis. These filamentous cells are able to pierce through the macrophage and release the fungus to infect other tissues. New technologies, including high-throughput FACS, genome-wide lentivirus RNAi libraries, and gene deletion libraries now allow for the systematic identification of host (macrophage) and pathogen (Candida) pathways that are fundamental to fungal pathogenesis. The identification of such pathways is essential for the development of new pharmaceutical targets that either specifically target Candida or stimulate enhanced macrophage/immune function. The goals of my proposal are to: 1. Use genome-wide RNAi libraries to identify macrophage genes required for phagocytosis of C. albicans and the induction of filamentation of phagocytosed Candida. 2. Identify Candida albicans mutants that have increased exposure of signature cell surface components by high throughput FACS and determine their role in responses inflammatory and phagocytic responses by macrophages. 3. Utilize the Candida cell surface mutants together with the macrophage knockdown lines to reconstruct the pathogen-macrophage recognition pathway. Relevance to public health: Systemic Candida infection is a life-threatening condition that has a mortality rate of 40%. The studies I have proposed will identify both fungal and host processes required for the success of Candida as a pathogen. Understanding the methods that Candida uses to avoid detection and killing by the immune system is the first step towards development of drugs to block these processes.
描述(由申请方提供):白色念珠菌是最常见的人类真菌病原体,已开发出几种逃避免疫检测和杀灭的机制。首先,念珠菌能够掩盖其细胞壁中的免疫原。其次,在巨噬细胞的吞噬作用下,念珠菌能够进行菌丝形态发生。这些丝状细胞能够穿透巨噬细胞并释放真菌感染其他组织。新技术,包括高通量流式细胞术,全基因组慢病毒RNAi文库和基因缺失文库,现在允许系统地鉴定宿主(巨噬细胞)和病原体(念珠菌)途径,这是真菌发病机制的基础。这些途径的鉴定对于开发特异性靶向念珠菌或刺激增强的巨噬细胞/免疫功能的新药物靶标至关重要。我的建议的目标是:1。使用全基因组RNAi文库鉴定吞噬C.白念珠菌和诱导吞噬的念珠菌分泌。2.通过高通量流式细胞术鉴定具有增加的特征细胞表面组分暴露的白色念珠菌突变体,并确定它们在巨噬细胞的炎症反应和吞噬反应中的作用。3.利用假丝酵母细胞表面突变体与巨噬细胞敲低细胞系一起重建病原体-巨噬细胞识别途径。与公共卫生的相关性:系统性念珠菌感染是一种危及生命的疾病,死亡率为40%。我提出的研究将确定念珠菌作为病原体成功所需的真菌和宿主过程。了解念珠菌用来避免被免疫系统检测和杀死的方法是开发药物阻止这些过程的第一步。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Valmik K. Vyas其他文献
Valmik K. Vyas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Valmik K. Vyas', 18)}}的其他基金
Recognition and Phagocytosis of Candida Albicans by the innate immune system
先天免疫系统对白色念珠菌的识别和吞噬作用
- 批准号:
7695003 - 财政年份:2007
- 资助金额:
$ 5.13万 - 项目类别:
Recognition and Phagocytosis of Candida Albicans by the innate immune system
先天免疫系统对白色念珠菌的识别和吞噬作用
- 批准号:
7739496 - 财政年份:2007
- 资助金额:
$ 5.13万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Lymph node-targeted codelivery of albumin-binding peptide antigens and di-adjuvant for melanoma combination immunotherapy
用于黑色素瘤联合免疫治疗的白蛋白结合肽抗原和双佐剂的淋巴结靶向共递送
- 批准号:
10522591 - 财政年份:2022
- 资助金额:
$ 5.13万 - 项目类别:
Lymph Node-Targeted Codelivery of Albumin-Binding Peptide Antigens and Di-Adjuvant for Melanoma Combination Immunotherapy
用于黑色素瘤联合免疫治疗的白蛋白结合肽抗原和双佐剂的淋巴结靶向共递送
- 批准号:
10884052 - 财政年份:2022
- 资助金额:
$ 5.13万 - 项目类别:
Identification of novel tumor antigens binding to canine HSP70, and their application to tumor immunotherapy
与犬HSP70结合的新型肿瘤抗原的鉴定及其在肿瘤免疫治疗中的应用
- 批准号:
17K08108 - 财政年份:2017
- 资助金额:
$ 5.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allosteric Binding in Antibodies and Protein Antigens
抗体和蛋白质抗原的变构结合
- 批准号:
7684654 - 财政年份:2008
- 资助金额:
$ 5.13万 - 项目类别:
Allosteric Binding in Antibodies and Protein Antigens
抗体和蛋白质抗原的变构结合
- 批准号:
8131731 - 财政年份:2008
- 资助金额:
$ 5.13万 - 项目类别:
Allosteric Binding in Antibodies and Protein Antigens
抗体和蛋白质抗原的变构结合
- 批准号:
7499132 - 财政年份:2008
- 资助金额:
$ 5.13万 - 项目类别:
Allosteric Binding in Antibodies and Protein Antigens
抗体和蛋白质抗原的变构结合
- 批准号:
7920187 - 财政年份:2008
- 资助金额:
$ 5.13万 - 项目类别:
Innate Cellular Lectin-Mediated Binding of Xenogeneic Antigens
先天细胞凝集素介导的异种抗原结合
- 批准号:
7282042 - 财政年份:2005
- 资助金额:
$ 5.13万 - 项目类别:
Innate Cellular Lectin-Mediated Binding of Xenogeneic Antigens
先天细胞凝集素介导的异种抗原结合
- 批准号:
6984696 - 财政年份:2005
- 资助金额:
$ 5.13万 - 项目类别:
Innate Cellular Lectin-Mediated Binding of Xenogeneic Antigens
先天细胞凝集素介导的异种抗原结合
- 批准号:
7484257 - 财政年份:2005
- 资助金额:
$ 5.13万 - 项目类别:














{{item.name}}会员




